Vitality Watch

Dossier pubmed review 10-oct-2026
Narrative review or expert overview without new data

Bone marrow adipose tissue in cardiometabolic disease: marrow niche remodeling, inflammatory hematopoiesis, and vascular pathology.

Key claim: Bone marrow adipose tissue is a metabolically active, endocrine and immunomodulatory marrow-niche component that expands with aging and cardiometabolic disease and may shape inflammatory hematopoiesis and vascular pathology, though its causal and therapeutic relevance to cardiovascular outcomes remains unresolved.

Abstract

Bone marrow adipose tissue (BMAT) is increasingly recognized as a metabolically active, endocrine, and immunomodulatory component of the marrow niche rather than a passive fat depot. This narrative review synthesizes biological, imaging, epidemiological, and therapeutic evidence linking BMAT and marrow metabolic activation with cardiometabolic disease. BMAT arises from marrow stromal progenitors and exhibits depot-specific heterogeneity, endocrine activity, insulin responsiveness, and context-dependent expansion during aging, diabetes, obesity, menopause, osteoporosis, and chronic kidney disease. Mechanistically, experimental studies indicate that marrow adipocytes and adipocyte-lineage niche cells can influence hematopoiesis through metabolic and local signaling, whereas trained immunity is established primarily in HSPCs, myeloid progenitors, and monocyte/macrophage populations. Human MRI/MRS studies characterize BMAT quantity and composition, whereasF-FDG PET reflects non-BMAT-specific marrow activation associated with vascular inflammation and early atherosclerosis; direct BMAT-cardiovascular evidence remains limited. Emerging population imaging and genetic analyses support BMAT as a disease-associated phenotype, particularly for osteoporosis and fractures. Interventions affecting metabolic, inflammatory, skeletal, or marrow pathways have differing degrees of BMAT-related evidence, and none has established that modifying BMAT improves cardiovascular outcomes. This review identifies BMAT as an emerging research phenotype while emphasizing that its causal, prognostic, and therapeutic relevance to cardiovascular disease remains unresolved.

Why this matters

Bone marrow adipose tissue has historically been treated as a bone/hematopoietic-niche curiosity, but this review consolidates it as a candidate marrow-sourced link between aging, cardiometabolic disease, and vascular pathology via inflammatory hematopoiesis. That reframing joins BMAT to the inflammaging, immunosenescence, and clonal-hematopoiesis axes already tracked here, while explicitly leaving causality and therapeutic tractability for cardiovascular outcomes unresolved.

Source

Link

Briefing card

Bone marrow adipose tissue in cardiometabolic disease: marrow niche remodeling, inflammatory hematopoiesis, and vascular pathology.
Stage: review · pubmed · 10-oct-2026

If you've had a vertebral MRI that quantified marrow fat, researchers are now treating that number as a possible cardiometabolic-aging signal, not just a bone-health one — though it has no validated clinical use yet.

Bone marrow adipose tissue is a metabolically active, endocrine and immunomodulatory marrow-niche component that expands with aging and cardiometabolic disease and may shape inflammatory hematopoiesis and vascular pathology, though its causal and therapeutic relevance to cardiovascular outcomes remains unresolved.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1007/s12020-026-04824-z

build build 880 · 2bcef25 · 2026-11-18